84
84
62
62
42
42
45
45
39
39
16
16
38
38
49
49
17
17
11
11
2019
2010
Company (682)University (21)Hospital (4)Research Institution (1)
1 - 10 of 682
Sort by
Patent
Publication NumberJP 6695003 B2Filing StatusIssued PatentAvailabilityUnknownFiling Date2017-09-07Publication Date2020-04-22
Patent
Publication NumberUS 20200071415Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2018-03-09Publication Date2020-03-05
The present invention provides for use in treating and methods of treating pancreatic cancer, in particular, metastatic pancreatic cancer, comprising olaratumab, in combination with gemcitabine and nab-paclitaxel.
Patent
Publication NumberUS 20200062850Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2017-10-27Publication Date2020-02-27
The present disclosure relates to a combination of anti-human VEGFR-2 antibodies (Ramucirumab) and anti-human PD-L1 (durvalumab) antibodies for treating certain disorders, including advanced gastric or gastroesophageal junction adenocarcinomas, non-small cell lung cancer, and hepatocellular carcinomas. Sequences 3 & 4 represent Ramucirumab VL and VH; Sequences 7 & 8 those of Durvalumab.
Patent
Publication NumberEP 3595717 A1Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2018-03-09Publication Date2020-01-22
Patent
Publication NumberWO 2019231803 A1Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-05-23Publication Date2019-12-05
The present invention provides for use in treating and methods of treating soft tissue sarcoma with olaratumab, in combination with gemcitabine and docetaxel.
Patent
Publication NumberUS 20190233523Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2017-09-07Publication Date2019-08-01
The present invention provides preparation of medicaments for use in treating and methods of treating cancer, in particular, non-small cell lung cancer, comprising an anti-EGFR antibody, preferably necitumumab, in combination with an anti-PD-1 antibody, preferably pembrolizumab.
Patent
Publication NumberEP 3515940 A1Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2017-09-07Publication Date2019-07-31
Patent
Publication NumberCN 110036030 AFiling StatusPatent ApplicationAvailabilityUnknownFiling Date2017-09-07Publication Date2019-07-19
The present invention provides preparation of medicaments for use in treating and methods of treating cancer, in particular, non-small cell lung cancer, comprising an anti- EGFR antibody, preferably necitumumab, in combination with an anti-PD-1 antibody, preferably pembrolizumab.
Patent
Publication NumberUS 20190183972Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2017-05-26Publication Date2019-06-20
The present disclosure relates to a combination of ramucirumab and pembrolizumab and methods of using the combination to treat certain disorders, such as non-small cell lung cancer, urothelial cancer, biliary tract cancer, and advanced gastric or gastroesophageal junction adenocarcinoma.
Patent
Publication NumberZA 201608217 BFiling StatusIssued PatentAvailabilityUnknownFiling Date2016-11-28Publication Date2019-05-29
Combination of human antibodies that bind to human platelet-derived growth factor receptor alpha (PDGFR alpha), preferably olaratumab, and doxorubicin as a medicament for the treatment of soft tissue sarcoma.
We found 682 documents that match your Search
Patents: 382
Clinical Trials: 99
SEC Filings: 201

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in